Drug discovery and target validation in the p53 pathway [electronic resource] / David Lane.
Material type:![Film](/opac-tmpl/lib/famfamfam/VM.png)
Animated audio-visual presentation with synchonized narration.
Title from title frames.
Contents: Controlling cancer -- p53 discovery -- Oncoproteins -- SV40, Adeno and HPV -- The p53 protein -- Incidence of genetic changes in p53 in human cancers -- What does p53 do? -- The p53 pathway is blocked in many tumor cells -- p53 and HDM2 are connected by a negative feedback loop -- Mdm2 controls p53 -- Evidence for the fine regulation of the p53 response -- How does p53 cause advanced aging? -- Therapy approaches -- Gene therapy -- Activating p53 -- Targets for p53 activation -- Small peptides block p53/HDM interaction and activate p53 -- Peptide minimization and optimization -- Nutlin 3 specificity -- Thousands of compounds can be tested for their ability to activate p53-dependent transcription -- CYC202: a cdk inhibitor in clinical trial that is a non genotoxic activator of the p53 response -- CDK inhibition -- Regulation of p53 by ubiquitin like proteins -- Stress stimuli that control the activity of p53 -- New isoforms of p53.
Access restricted to subscribers.
Mode of access: World Wide Web.